Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner-Reference-Cited by-同舟云学术

Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner

Published:2017-05-15 Issue:8 Volume:11 Page:1035-1049
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Hsieh Feng-Shu¹²,Chen Yao-Li³⁴,Hung Man-Hsin⁵⁶,Chu Pei-Yi⁷⁸,Tsai Ming-Hsien¹²,Chen Li-Ju¹²,Hsiao Yung-Jen¹²,Shih Chih-Ting¹²,Chang Mao-Ju¹²,Chao Tzu-I⁹,Shiau Chung-Wai¹⁰,Chen Kuen-Feng¹²^ORCID

Affiliation:

1. Department of Medical Research; National Taiwan University Hospital; Taipei Taiwan

2. National Center of Excellence for Clinical Trial and Research; National Taiwan University Hospital; Taipei Taiwan

3. Department of Surgery; Changhua Christian Hospital; Taiwan

4. School of Medicine; Kaohsiung Medical University; Taiwan

5. Division of Medical Oncology; Department of Oncology; Taipei Veterans General Hospital; Taiwan

6. School of Medicine; National Yang-Ming University; Taipei Taiwan

7. Department of Pathology; Show Chwan Memorial Hospital; Changhua Taiwan

8. School of Medicine; College of Medicine; Fu-Jen Catholic University; New Taipei Taiwan

9. Transplant Medicine & Surgery Research Centre; Changhua Christian Hospital; Taiwan

10. Institute of Biopharmaceutical Sciences; National Yang-Ming University; Taipei Taiwan

Funder

Ministry of Science and Technology

National Taiwan University Hospital

National Health Research Institutes

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/1878-0261.12072/fullpdf

Reference50 articles.

1. The history and future of targeting cyclin-dependent kinases in cancer therapy;Asghar;Nat Rev Drug Discov,2015

2. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6;Baughn;Can Res,2006

3. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma;Bollard;Gut,2016

4. S100 proteins in cancer;Bresnick;Nat Rev Cancer,2015

5. Activation of protein phosphatase 5 by limited proteolysis or the binding of polyunsaturated fatty acids to the TPR domain;Chen;FEBS Lett,1997

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer;Advanced Science;2024-08-13

2. Abemaciclib and Vacuolin-1 decrease aggregate-prone TDP-43 accumulation by accelerating autophagic flux;Biochemistry and Biophysics Reports;2024-07

3. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects;Molecular Pharmaceutics;2024-06-18

4. Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect;Translational Oncology;2024-06

5. Improving Dissolution Rate and Solubility of Palbociclib Salts/Cocrystal for Anticancer Efficacy;Journal of Molecular Structure;2024-06